Soquelitinib is a potential first-in-class ITK inhibitor with broad potential in cancer and immune diseases There are currently no fully approved agents for the treatment of relapsed PTCL and soquelitinib has been granted Orphan Drug Designation and Fast Track Designation by the FDA BURLINGAME,

BURLINGAME, Calif. , Sept. 03, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals , Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller , M.D., president and chief executive officer, and Jeffrey Arcara , chief business officer, will conduct

Early Results from Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Demonstrate Clinical Activity and Corresponding Changes in Cytokine Levels Consistent with ITK Inhibition Mechanism of Action Soquelitinib Registration Phase 3 Trial in Peripheral T Cell Lymphoma (PTCL) Advancing Toward

Soquelitinib registrational Phase 3 clinical trial in PTCL advancing toward initial enrollment in Q3 2024 Fast track designation underscores unmet need for patients with relapsed or refractory PTCL, an indication with poor overall outcomes and no approved drugs based on randomized trials

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT BURLINGAME, Calif. , July 31, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals , Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on August

Data demonstrated in vitro and in vivo ITK inhibition with soquelitinib induced switching of proinflammatory Th 17 cells into anti-inflammatory T reg cells Publication confirms and extends understanding of ITK inhibition mechanism of action and its potential in inflammatory autoimmune and allergic

BURLINGAME, Calif. , May 30, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals , Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller , M.D., president and chief executive officer, and Jeffrey Arcara , chief business officer, will conduct one-on-one

Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024 Soquelitinib Registration Phase 3 Trial in Peripheral T Cell Lymphoma Advancing Toward Initial Enrollment in Q3 2024 Interim Data from Ciforadenant Phase 1b/2

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT BURLINGAME, Calif. , May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals , Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on May 6,

BURLINGAME, Calif. , May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today announced that it has entered into a securities purchase agreement with new and existing investors to raise

Atopic dermatitis is the first immune disease indication being studied in the clinic for soquelitinib, the Company’s selective ITK inhibitor Corvus anticipates releasing initial clinical data from trial before year-end 2024 BURLINGAME, Calif. , April 09, 2024 (GLOBE NEWSWIRE) -- Corvus

Soquelitinib advancing towards initial enrollment for registrational Phase 3 clinical trial for PTCL and randomized Phase 1 clinical trial for atopic dermatitis Orphan drug designation and new interim data from Phase 1/1b clinical trial further demonstrate soquelitinib’s potential to address the

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT BURLINGAME, Calif. , March 13, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals , Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March

Poster presentation unveils Corvus’ next-generation ITK inhibitor candidates designed to deliver precise T cell modulation for immunology indications BURLINGAME, Calif. , Feb. 12, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals , Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company,

Company on track to initiate soquelitinib Phase 3 registrational clinical trial in PTCL BURLINGAME, Calif. , Feb. 08, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals , Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the U.S.

BURLINGAME, Calif. , Feb. 06, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals , Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced the appointment of Jeffrey Arcara as Chief Business Officer. Mr. Arcara , who is a proven leader with more than 30 years of commercial

BURLINGAME, Calif. , Jan. 23, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals , Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, is deeply saddened to announce the passing of Edith P. Mitchell , M.D., a valued member of the Board of Directors.